Magtrace bracketing to guide lumpectomy and sentinel node biopsy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In early-stage breast cancer, precise localization of the lesion and sentinel lymph node is crucial for complete tumor removal and accurate staging. This trial uses superparamagnetic iron oxide (Magtrace) for bracketing the lesion and guiding sentinel node localization during breast-conserving surgery. The approach aims to reduce reliance on radioactive materials and wires, potentially improving patient comfort and workflow. Eligible participants are those undergoing lumpectomy with planned bracketing and sentinel node biopsy, under the care of the King Faisal Specialist Hospital & Research Center. The study observes safety and practicality of the Magtrace bracketing technique in real surgical settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

All patients with breast cancer undergoing breast conserving surgery requiring bracketing of the area of excision (as determined by the multidisciplinary tumor board) and a sentinel lymph node biopsy for axillary staging.

Exclusion Criteria:

1. Patients having mastectomy.
2. Patients unfit for breast conserving surgery due to inability to have adjuvant radiotherapy.
3. Patients requiring axillary clearance without sentinel node biopsy.
4. Patient undergoing breast conserving surgery without need for sentinel node biopsy.
5. Patient with metastatic breast cancer requiring palliative surgery for local control.
6. Patients not consenting for research.
7. Patient with allergy to Magtrace.

Where it's running

• King Faisal Specialist Hospital and Research Center
  Madinah, Saudi Arabia Recruiting

Study contacts

• Principal investigator: Fayyaz A Mazari, MBBS, MSc, MS, PhD, FRCS, FEBS — King Faisal Specialist Hospital & Research Center
• Study coordinator: Fayyaz A Mazari, MBBS, MSc, MS, PhD, FRCS, FEBS
• Email: fmazari@kfshrc.edu.sa
• Phone: +966 12667 7777

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Personalized cardiac imaging approach for women with early breast cancer on HER2 therapy

  This study tests a personalized, risk-based plan to reduce unnecessary heart imaging while still catching heart problems early in women with HER2-positive breast cancer receiving HER2-targeted therapy.

  Recruiting University of Rochester · Rochester, New York · NCT07630402

• Bone density changes with anti-PD-1 immunotherapy

  This pilot will test if anti-PD-1 immunotherapy changes bone density in adults starting approved anti-PD-1 treatment for certain early-stage cancers.

  Recruiting Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07555210

• Endoscopic nipple-sparing mastectomy through a single hidden axillary incision

  This project will test whether endoscopic nipple‑sparing mastectomy performed through one hidden armpit incision is safe and practical for women with early‑stage breast cancer or DCIS who want immediate implant reconstruction.

  Recruiting Fondazione del Piemonte per l'Oncologia · Candiolo, Turin · NCT07507890

• Combining hormone therapy with chemotherapy and HER2-targeted treatment before surgery for HER2+ breast cancer

  This trial will try giving hormone (endocrine) therapy at the same time as chemotherapy and HER2-targeted drugs for adults with HR+, HER2+ breast cancer to see if tumors respond better before surgery.

  Recruiting at 4 sites Phase 2 Legacy Health System · Gresham, Oregon and 3 other locations · NCT07506876

• SIRA-1000 radiofrequency ablation of lumpectomy margins

  This study tests whether using the SIRA-1000 radiofrequency device at the edge of the lumpectomy cavity during breast-conserving surgery can destroy remaining cancer cells in women 50 and older with ER/PR+ invasive ductal breast cancer.

  Recruiting Innoblative Designs, Inc. · Galveston, Texas · NCT07206121

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.